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Objective. To examine the effect of metabolic syndrome and psoriatic disease-related variables on coronary plaque burden in psoriatic arthritis (PsA) patients.
Methods. Fifty PsA patients without symptoms of coronary artery disease (CAD) (25 with metabolic syndrome and 25 without metabolic syndrome) and 50 ageand sex-matched controls underwent 64-slice coronary computed tomography angiography. Plaque localization, segment involvement score (SIS), segment stenosis score (SSS), and total plaque volume (TPV) were calculated. Plaques were classified as calcified, mixed, or noncalcified. Kruskal-Wallis test, rank correlations, and linear regression analyses were used to study the relationship between PsA, metabolic syndrome, and plaque burden.
Results. Plaques were found in 76% of PsA patients versus 44% of controls (P = 0.001), and a higher proportion of patients with PsA had affected coronary vessels (P = 0.007). SIS, SSS, and TPV were greater in PsA patients than controls (P = 0.003, P = 0.001, and P ≤ 0.001, respectively). More PsA patients had mixed plaques, and mixed plaque volume was higher than in controls (P < 0.001). PsA patients with metabolic syndrome and those without metabolic syndrome had similar plaque burdens and types. SIS, SSS, and TPV did not show significant relationships with features of metabolic syndrome, but did significantly correlate with disease activity measures. TPV was associated with a diagnosis of PsA (B = 0.865, P = 0.008), but not with metabolic syndrome. Age, highest C-reactive protein level, highest swollen joint count, disease duration, and plasma glucose level were independent predictors of higher plaque burden in PsA.
Conclusion. PsA is associated with accelerated coronary plaque formation, particularly mixed plaques, independent of metabolic disease. Psoriatic disease activity and severity may predict coronary plaque burden better than traditional risk factors.
Psoriatic arthritis (PsA) is a chronic immunemediated inflammatory disease that affects peripheral joints, entheses, and axial sites along with skin and nails (1) . Approximately 14-30% of patients with psoriasis develop PsA (2, 3) . In addition to the characteristic extraarticular features, such as inflammatory bowel disease and uveitis, PsA is associated with comorbidities, including obesity, diabetes, metabolic syndrome, cardiovascular disease (CVD), nonalcoholic fatty liver disease, osteoporosis, and depression (1, 4, 5) .
Although data on cardiovascular risk in patients with psoriatic disease are limited, a growing body of literature suggests that patients with psoriasis and PsA have an increased prevalence of cardiovascular risk factors and are at greater risk for subsequent major cardiovascular events compared with the general population (6) (7) (8) (9) (10) (11) (12) . The standardized prevalence ratio for coronary artery disease (CAD) in patients with PsA ranges from 1.3 to 2.57 (13) .
In a large population-based study, PsA patients displayed a higher risk of myocardial infarction compared to controls, similar to those with severe psoriasis and patients with rheumatoid arthritis (RA) not prescribed a diseasemodifying antirheumatic drug (DMARD) (14) .
The high rates of cardiovascular events in PsA may be attributed to either accelerated formation of coronary plaques or to increased prevalence of rupture-prone, vulnerable plaques, or both. Coronary computed tomography angiography (CCTA) is an established noninvasive cardiovascular imaging method that assesses CAD, offering quantitative measurement of stenosing and nonstenosing coronary plaque burden along with qualitative assessment of plaque composition (15, 16) . CCTA outperforms traditional noninvasive options for risk stratification in CAD, and it has been shown to be as accurate as invasive angiography for detecting ischemia-causing lesions (17) . Moreover, it also has prognostic utility in asymptomatic high-risk patients (18, 19) . Previous studies using CCTA demonstrated a higher prevalence of coronary artery plaques in psoriasis, and more recently in RA and PsA patients without a diagnosis of CAD, compared to controls. Studies have also assessed the prevalence of obstructive coronary stenosis in PsA patients using CCTA (20) (21) (22) . However, no studies to date have provided detailed coronary plaque volume measurements in patients with PsA. Measuring overall coronary plaque volumes provides a more meaningful prognostic assessment in asymptomatic patient populations and has been shown to be strongly predictive of subsequent hard cardiac events, including unstable angina, myocardial infarction, and cardiac death (18, 23) .
Metabolic syndrome, a constellation of cardiovascular risk factors including obesity, hypertension, dyslipidemia, and insulin resistance, has an increased prevalence in PsA, and it independently associates with the severity of underlying PsA (3, 5) . Metabolic abnormalities may contribute to the higher frequency of clinical and subclinical CVDs in PsA; however, chronic inflammation, which plays a pivotal role in the pathogenesis of atherosclerosis and plaque destabilization, also appears to be an important driving factor (24, 25) . Previous ultrasound studies showed higher prevalence of carotid atherosclerosis in PsA patients without diagnosis of CVD independent of traditional cardiovascular risk factors (26) . It is still under debate whether high prevalence of metabolic abnormalities leads to increased cardiovascular morbidity in PsA, or whether PsA is an independent risk factor for cardiovascular events.
In the present study, we hypothesized that PsA patients with well-established disease without symptoms of CAD would have higher coronary plaque burden compared to controls, and that this might be associated with underlying disease-related variables. The objectives of our study were: 1) to evaluate the type and extent of coronary plaques by performing detailed plaque volume measurements in PsA compared to age-and sex-matched controls using a 64-slice CCTA; and 2) to identify clinical associations of plaque measurements by examining likely contributing features including metabolic syndrome and psoriatic disease-related variables.
PATIENTS AND METHODS
Patients and controls. Fifty PsA patients who fulfilled the criteria of the Classification of Psoriatic Arthritis Study Group (27) , had no prior history of CAD, and were ages 18-80 years were invited to participate in this single-center controlled study. Patients were taken from a consecutive cohort of 283 white patients attending rheumatology clinics at St. Vincent's University Hospital (SVUH) between 2011 and 2012 (5). We selected 25 patients with metabolic syndrome as defined by the National Cholesterol Education Program Adult Treatment Panels III criteria (28) and 25 patients without metabolic syndrome.
Fifty controls were selected retrospectively from a cohort of patients with no history of CAD who had a CCTA at SVUH, through a search of our institution's Radiology Information System. Indications for CCTA were atypical chest pain (n = 30), family history of CAD (n = 5), inconclusive exercise stress test (n = 5), hyperlipidemia (n = 4), risk factors for CAD (n = 3), shortness of breath on exertion (n = 1), abnormal electrocardiogram (EKG; n = 1), and syncope (n = 1). Controls were matched for age, sex, smoking status, and metabolic risk factors. Exclusion criteria were known allergy to iodinated contrast, baseline renal insufficiency (glomerular filtration rate <60 ml/minute), atrial fibrillation, tachycardia (>100 beats/minute at rest), resting systolic blood pressure (BP) <100 mm Hg, contraindication to beta-blocker or nitroglycerin, pregnancy, autoimmune syndromes, active malignancy, and known history of CAD (prior myocardial infarction, percutaneous transluminal coronary angioplasty or intracoronary stent, or coronary artery bypass surgery).
Written informed consent was obtained from all study participants according to the Declaration of Helsinki. The study was approved by St. Vincent's Healthcare Group Ethics and Medical Research Committee.
Demographic characteristics and clinical assessment. Demographic data collected included age, sex, smoking status, alcohol intake (units/week), duration of psoriasis and PsA, and current use of conventional DMARDs and/or biologic DMARDs. Clinical variables included highest-ever 68-joint tender joint count (TJC), highest-ever 66-joint swollen joint count (SJC), and clinically deformed joint count as defined by the number of joints with fixed deformities, flail, fused, or surgically replaced joints. Presence of dactylitis, enthesitis, arthritis mutilans, sacroiliitis, axial disease, and radiographic evidence of deformed or fused joints, erosions, or osteolysis were recorded. Psoriasis Area and Severity Index (PASI) (29) , highest-ever PASI, body surface area, and the presence of nail involvement were documented. We calculated Composite Psoriatic Disease Activity Index (CPDAI) (30) and patient-reported outcome measures such as Dermatology Life Quality Index, Health Assessment Questionnaire, and Bath Ankylosing Spondylitis Disease Activity Index (31, 32) .
Laboratory and metabolic risk factor evaluation. Laboratory assessments included fasting venous blood samples for glucose, insulin, and lipid profile, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) level. We also recorded the highest ESR and CRP level during the disease course. The median duration of follow-up was 19 years from the initial symptoms of PsA. The homeostatic model assessment for insulin resistance was calculated as previously described (5) . Fasting glucose and insulin data were not available for the controls. Body mass index (BMI) was calculated as the patient's weight in kilograms divided by height in meters squared. Metabolic syndrome was diagnosed when a patient had at least 3 of the following 5 conditions: central obesity (waist circumference ≥102 cm in men and ≥88 cm in women), triglycerides ≥1.7 mmoles/liter, high-density lipoprotein (HDL) cholesterol <1 mmole/liter in men and <1.3 mmoles/liter in women, hypertension (documented history of high BP, current antihypertensive treatment, or BP ≥130/85 mm Hg on 2 separate outpatient visits ≥6 weeks but ≤6 months apart), and fasting glucose ≥5.6 mmoles/liter (28) .
CCTA image acquisition. CCTA was acquired on a 64-slice single-source CT scanner (Siemens Sensation). Images were acquired with retrospective EKG-gating and slice thickness of 0.6 mm, slice overlap of 0.3 mm, gantry rotation time of 330 milliseconds, 120 kVp, and 800-850 mAs. Fifty to 100 mg of oral metoprolol (Bedford Laboratories) was administered to patients 1 hour before image acquisition, depending on the initial heart rate. If the heart rate remained above 65 beats per minute, multi-segment reconstruction was utilized. A timing bolus technique was used to ascertain the optimal time to commence image acquisition (20 ml of contrast medium injected at 5-6 ml/second with a region of interest placed over the ascending aorta). Images were acquired during a single breath hold in mid-inspiration following the administration of sublingual glyceryl trinitrate for coronary vasodilatation. Seventy to 90 ml of iodinated contrast medium (Iopamidol 340; Bracco Diagnostics) was injected at a rate of 5-6 ml/second followed by a 20-ml saline bolus chaser injected at 6 ml/second.
CCTA image analysis. CCTA images were analyzed by 4 independent experienced readers (GMH, CER, HF, and JDD) who were blinded with regard to the subjects' clinical characteristics. Plaque localization within the coronary tree was described by documenting the major coronary artery segments, including the left main, left anterior descending, left circumflex, and right coronary artery segments (15-segment model) using the Society of Cardiovascular CT reporting nomenclature (16, 33) .
Plaque volume measurements were performed using a previously described technique (34) . Briefly, axial multiplanar reconstruction images of each coronary plaque were obtained at 0.5-mm increments. The total plaque area on each axial multiplanar reconstruction slice was manually traced. Total plaque volume (TPV) was calculated by multiplying the sum of the individual plaque slice areas by the slice increment. Plaque type was classified as calcified, mixed, or noncalcified based on the density of the plaque compared to the contrast-enhanced lumen (35) . Mean, minimal, and maximal CT attenuations of the respective lesions were assessed in Hounsfield units. CT attenuation within the plaque was measured using a circular region of interest placed in the center of the plaque (36) .
Each segment was scored for stenosis severity on a scale of 0-4 based on grade of luminal restriction, where 0 = 0% (absence of plaque), 1 = <25% (nonsignificant), 2 = 25-49% (mild stenosis), 3 = 50-69% (moderate stenosis), and 4 = >70% (severe stenosis) (33) . In cases of multiple plaques, the most stenotic one was assigned to the specific segment. The segment involvement score (SIS), defined as the total number of segments with plaque per patient (0-15), and the segment stenosis score (SSS), defined as the sum of the stenosis severity scores over 15 segments (0-60), were calculated (21, 37) .
Statistical analysis. Statistical analysis was performed using SPSS version 20. Clinical characteristics of the study subjects were reported as the mean AE SD for continuous variables and percentage for categorical variables. Differences between PsA patients with and those without metabolic syndrome and controls were compared using Mann-Whitney U test for continuous variables and Fisher's exact test and chisquare test for categorical variables. Kruskal-Wallis test was applied to study the effect of PsA-related variables and factors of metabolic syndrome on the number of affected coronary vessels. Rank correlation was used to analyze the relationship between variables of disease characteristics, components of metabolic syndrome, and SIS, SSS, and TPV in PsA. Linear regression was used to study the relationship between PsA, metabolic syndrome, and TPV. Linear and multiple linear regression analyses were performed to identify disease-related variables and cardiovascular risk factors associated with coronary plaque burden (TPV, SIS, and SSS) in PsA. P values less than 0.05 were considered significant.
RESULTS
Patient characteristics. We enrolled 50 patients (23 women and 27 men) with a mean AE SD age of 58.3 AE 8.2 years. Twenty-five of the patients had metabolic syndrome, and 25 did not. Comparisons of demographic and disease-specific characteristics between the entire PsA group and controls, and between patients with PsA with metabolic syndrome and patients with PsA without metabolic syndrome, are summarized in Table 1 . All patients were white, the mean AE SD age at onset of psoriasis was 32.2 AE 13.8 years, and the mean AE SD age at onset of PsA was 37.1 AE 12.1 years. The mean AE SD disease duration of PsA was 18.7 AE 7.8 years. PsA patients with metabolic syndrome had a longer disease duration than those without metabolic syndrome (P = 0.051). Forty-seven patients (94%) had predominantly peripheral disease, and 3 patients (6%) had axial involvement exclusively. Most PsA patients had mild or moderately severe psoriasis, with a mean AE SD maximum PASI of 4.7 AE 4.8. There were no significant differences between the 2 groups in joint-and skin-related outcomes, disease activity measures, or patient-reported outcome measures. Thirty-two patients (64%) were receiving conventional DMARDs, and 33 patients (66%) were receiving biologic DMARDs. Sixteen of the patients (32%) were receiving combination therapy (Table 1) .
Since our patients were not randomly selected, we examined whether the present study cohort truly represents PsA patients in general. We compared the metabolic profile of our 50 PsA patients with CCTA data to the 233 PsA patients who were not selected for CCTA 398 SZENTPETERY ET AL from a consecutive cohort of 283 patients with established disease. Other than older age and a higher proportion of patients with HDL cholesterol <1 mmole/liter in the group selected for CCTA in the present study (the latter difference approached significance), there were no significant differences between patients who were selected for CCTA and those who were not, including the proportion of men, smokers, patients with metabolic syndrome, and risk factors for CAD (Table 2) .
Cardiovascular risk factors.
PsA patients were well matched with controls for age, sex, and cardiovascular risk factors. Forty-two percent of PsA patients and 28% of controls were current or former smokers. There were more patients with hypertension and low HDL cholesterol level in the PsA group than in the control group, while the numbers of patients with diabetes, elevated BMI, and elevated triglycerides were comparable in both groups ( Table 1) .
Comparisons of cardiovascular risk factors between PsA patients with metabolic syndrome and those without metabolic syndrome, and between each PsA group and the control group, are shown in Table 1 . Groups were well balanced for sex and smoking. Patients with metabolic syndrome were older than controls (P = 0.09). There were significantly more patients with central obesity, hypertension, elevated triglycerides, low HDL cholesterol level, and diabetes in the group with metabolic syndrome than in the control group, while the number of patients with cardiovascular risk factors in the group without metabolic syndrome was similar to that in the control group.
Coronary artery involvement in PsA patients and controls. More PsA patients than controls had coronary artery involvement (76% versus 44%; P = 0.001). One-, 2-, and 3-vessel disease was present in 42%, 14%, and 20%, respectively, of PsA patients compared with 20%, 14%, and 10%, respectively, of controls (P = 0.007) ( Figure 1A ). The proportion of subjects with coronary plaque was higher in PsA patients without metabolic syndrome (80%) 19 (38) 59 (25) * PsA = psoriatic arthritis; BMI = body mass index; BP = blood pressure; HDL = high-density lipoprotein. † P = 0.031 versus PsA with coronary computed tomography angiography (CCTA). ‡ P = 0.051 versus PsA with CCTA. Figure 1 . A, Proportion of patients with psoriatic arthritis (PsA), controls, patients with PsA without metabolic syndrome (Nmetsy), and patients with PsA with metabolic syndrome (Metsy) who had no coronary artery disease (CAD) or 1-, 2-, or 3-vessel CAD. B, Proportion of patients with PsA, controls, patients with PsA without metabolic syndrome, and patients with PsA with metabolic syndrome who had no stenosis (0), clinically nonsignificant stenosis (<25% luminal restriction), mild stenosis (25-49% luminal restriction), moderate stenosis (50-69% luminal restriction), or severe stenosis (>70% luminal restriction). * = P < 0.05; ** = P ≤ 0.001, by Fisher's exact test and chi-square test. 400 SZENTPETERY ET AL than in controls (P = 0.003), while it was similar to that in PsA patients with metabolic syndrome (72%). Assessing coronary artery involvement for 15 segments, we found that more PsA patients had left anterior descending 1 and left anterior descending 2 involvement compared to controls (60% versus 32% [P = 0.005] and 36% versus 16% [P = 0.023], respectively). Figure 1B shows the proportion of patients with coronary stenosis stratified by severity of luminal stenosis for each group. Only 22% of PsA patients were stenosis free compared to 56% of controls (P = 0.001), and there were more patients with moderate stenosis in the PsA group than in the control group (22% versus 6%; P = 0.044). Clinically nonsignificant, mild, moderate, and severe stenosis was present in 26%, 16%, 22%, and 14%, respectively, of PsA patients compared with 22%, 8%, 6%, and 8%, respectively, of controls (P = 0.005). There were no significant differences in the number of patients with various grades of stenosis severity between those with metabolic syndrome and those without metabolic syndrome. Representative CCTA images of severe, 3-vessel obstructive disease in a PsA patient asymptomatic for CAD are shown in Figure 2 .
Quantitative measurements and composition of coronary plaques. Mean quantitative plaque scores (SIS, SSS, and TPV) were higher in PsA patients than controls (P = 0.003 for SIS, P = 0.001 for SSS, and P ≤ 0.001 for TPV) (Figures 3A-C) . While quantitative scores were similar in those with metabolic syndrome and those without metabolic syndrome, SSS and TPV were significantly higher in both groups compared to controls. Plaque volume was higher in PsA patients in 9 of the 15 coronary segments, in particular in the left anterior descending 1 segment and left circumflex 2 segment (P = 0.094 and P = 0.064, respectively). Calcified plaque, mixed plaque, and noncalcified plaque were present in 36%, 60%, and 16%, respectively, of PsA patients and 26%, 22%, and 12%, respectively, of controls. More PsA patients had mixed plaque than controls (P < 0.001), both PsA patients with metabolic syndrome and those without metabolic syndrome (P = 0.009 and P < 0.001 versus controls, respectively). The mixed plaque volume was higher in PsA patients (mean AE SD 0.58 AE 0.9), particularly in the group of patients without metabolic syndrome (mean AE SD 0.89 AE 1.2) compared to controls (mean AE SD 0.21 AE 0.6) (P < 0.001), while calcified plaque and noncalcified plaque volumes were similar ( Figure 3D ). Effects of PsA-related variables, features of metabolic syndrome, and treatment on coronary plaques. We studied the effect of disease-related variables and cardiovascular risk factors (listed in Table 1 ) on the number of affected coronary vessels (0, 1, 2, or 3) and on quantitative plaque scores (SIS, SSS, and TPV). Central obesity, maximum TJC, maximum SJC, and maximum CRP level had a significant effect on the number of coronary arteries with plaques (P = 0.017, P = 0.039, P = 0.024, and P = 0.006, respectively), but PsA disease duration and CPDAI also had a strong effect (P = 0.053 and P = 0.055, respectively). Maximum TJC correlated with SIS (q = 0.49, P = 0.009) and SSS (q = 0.45, P = 0.019), maximum ESR associated with SIS (q = 0.39, P = 0.006), SSS (q = 0.49, P = 0.001), and TPV (q = 0.32, P = 0.028), and maximum CRP level associated with SIS (q = 0.48, P ≤ 0.001), SSS (q = 0.44, P = 0.002), and TPV (q = 0.38, P = 0.007).
Surprisingly, none of the components of metabolic syndrome showed significant correlations with quantitative plaque scores. Finally, we examined whether biologic DMARDs have a protective effect on coronary plaque formation. In our cohort of patients, no significant differences in any of the quantitative plaque measures were observed between PsA patients treated with conventional DMARDs (n = 32) and those treated with biologic DMARDs (n = 33).
Impact of smoking on the presence of coronary plaques in PsA. Linear and logistic regression analyses were used to study the effect of smoking on coronary plaque burden in PsA patients. We did not find a strong relationship between smoking and the number of affected coronary vessels, SIS, TPV, or volumes of calcified plaque, mixed plaque, and noncalcified plaque. Interestingly, when comparing PsA patients who ever smoked (n = 21) to those who never smoked (n = 29), we found significantly more patients with plaques in the smoking group (90% versus 66%) (odds ratio Predictors of coronary plaque burden. We analyzed whether the presence of PsA or metabolic syndrome influenced TPV. Linear regression analysis revealed no significant relationship between metabolic syndrome and TPV, while diagnosis of PsA was an independent predictor of TPV (B = 0.865 [95% CI 0.236, 1.493], P = 0.008).
To study the relationship between plaque burden (TPV, SSS, and SIS) and PsA, linear regression (including PsA-related variables and components of the metabolic syndrome listed in Table 1 ) and multiple linear regression (backward) analyses (including variables demonstrating significant association with plaque burden with simple linear regression analyses) were performed. Linear regression analyses showed associations between TPV and disease duration, maximum TJC, maximum CRP level, and plasma glucose level. SSS associated with age, maximum TJC, and maximum SJC. SIS associated with age, disease duration, presence of erosions, maximum TJC, maximum SJC, number of deformed joints, and maximum CRP level. Multiple regression revealed significant relationships between TPV and plasma glucose level. In multiple linear regression analysis, SSS associated with age and maximum SJC, whereas age, disease duration, and maximum CRP were predictors of SIS (Table 3) .
DISCUSSION
Our study demonstrates that PsA patients without symptoms of or a diagnosis of CAD have a higher number of and more extensive coronary plaques, particularly of mixed type, compared to age-and sex-matched controls as measured by CCTA. Quantitative plaque scores did not show a significant relationship with metabolic syndrome, but did correlate significantly with PsArelated variables such as maximum TJC, maximum ESR, and maximum CRP level. We demonstrated that TPV in the coronary arteries was associated with a diagnosis of PsA, but not with metabolic syndrome. Besides age, maximum SJC, maximum CRP level, disease duration, and plasma glucose level were independent predictors of higher plaque burden in PsA.
Patients with psoriasis and PsA have an increased risk of clinical and subclinical CVDs, largely due to accelerated atherosclerosis (25) . Ultrasonographic measurements of carotid artery plaque burden suggested that patients with PsA have more severe subclinical atherosclerosis than patients with psoriasis alone (38) . The "psoriatic march" concept suggests that chronic systemic inflammation, a feature of severe psoriasis and PsA, leads to insulin resistance, resulting in endothelial dysfunction and atherosclerosis (39) . Chronic inflammation acts independently and/or synergistically with conventional risk factors (25, 40) . Several features, such as an increased prevalence of smoking, altered lipid profile, diabetes, hypertension, increased fibrinogen level, enhanced number of platelets, and hypercoagulability, might explain the greater cardiovascular risk in PsA. The link between CVDs and PsA may also be mediated by a decline in physical activity, presence of HLA-B27, undertreatment, or poor compliance with management of cardiovascular risk factors (12, 41, 42) .
To assess CAD in PsA, we used 64-slice CCTA, a noninvasive, highly accurate and reproducible imaging technique, that directly examines the coronary artery wall and provides information on coronary plaque localization, size, composition, and severity of luminal restriction (15) (16) (17) (18) (19) . A major advantage of CCTA over invasive angiography is its ability to assess the nonstenosing atherosclerosis burden within the vessel wall, which is underestimated on invasive coronary angiography. Data on CAD using CCTA is limited in psoriasis, and only a single study has applied CCTA in PsA to date (22) . In psoriasis, increased prevalence and severity of coronary artery calcification compared to healthy controls has been reported, similar to that of patients with type 2 diabetes mellitus (20, 43) . Interestingly, increased coronary plaque burden in psoriasis as measured by CCTA was found to be associated with depression (44) .
We showed a higher prevalence and extent of coronary plaques in our PsA cohort compared to controls and that all quantitative plaque measures (SIS, SSS, and TPV) were higher in PsA. Shen at al also reported increased prevalence, burden, and severity of all types of coronary plaques in a cohort of Chinese patients with PsA without prior diagnosis of CAD compared to controls; however, that study did not provide detailed plaque volume measurements (22) . The proportion of patients with coronary plaques (76% versus 60%) and with calcified plaques (36% versus 32%) were comparable in our study and the study by Shen et al, while we found a higher prevalence of mixed plaque (60% versus 22%) and more patients with stenosis >50% (36% versus 8.9%) in our cohort. Besides ethnicity, these differences are likely due to more severe underlying disease in our group as reflected by longer disease duration, higher deformed joint count, and higher proportion of patients treated with biologic DMARDs.
Moreover, we showed that a higher percentage of PsA patients had plaques in the proximal left anterior descending coronary segments, with greater TPV in the proximal left anterior descending artery, compared to controls. Our results may further support the link between PsA and increased risk of CAD, since SIS has been shown to be predictive of major adverse cardiac events in asymptomatic patients with a high "a priori" risk of CAD. Furthermore, lesions located in the large proximal (left main or proximal left anterior descending) coronary segments are known to be associated with a poorer prognosis (18, 45) .
One of the most notable findings of our study was that not only the proportion of patients with mixed plaque, but also the mean mixed plaque volume was significantly higher in PsA patients compared to controls, while we did not observe significant differences for calcified plaque and noncalcified plaque. It has been shown that lipidrich, rupture-prone mixed and noncalcified plaques are more prevalent in patients presenting with acute coronary syndromes, and are associated with a higher cardiovascular risk than calcified plaques, which are more dominant in stable coronary disease (46) . Moreover, thin-cap fibroatheromas, a key component of the vulnerable plaque, are more frequently observed in lesions classified as mixed (47) . The higher prevalence and extent of mixed plaque found in our patients may strengthen the wellestablished relationship between PsA and the higher frequency of cardiac events. However, translating the identification of elevated coronary plaque burden in PsA patients into preventative interventions to reduce future cardiovascular events remains challenging. While there is a lack of evidence for more aggressive treatment for reducing the risk of adverse cardiovascular outcomes, our findings, that psoriatic disease activity and severity may predict coronary plaque burden better than traditional risk factors, suggest that achieving minimal disease activity or remission may have a beneficial effect in preventing future cardiovascular events in PsA.
PsA patients with metabolic syndrome had similar coronary plaque burden, quantitative plaque measures (SIS, SSS, and TPV), and plaque composition compared to those without. Furthermore, we showed that there was no significant relationship between TPV in the coronary arteries and metabolic syndrome. A diagnosis of PsA was an independent predictor of higher coronary TPV, supporting 404 SZENTPETERY ET AL the hypothesis that PsA per se could be considered an independent risk factor for accelerated atherosclerosis. The relationship between inflammation and atherogenesis is well recognized in PsA, yet studies on the impact of disease activity on CVDs are scarce. In a large cohort of PsA patients, higher ESR and damaged joint count were associated with more severe carotid artery atherosclerosis (13, 24) . Consistent with that study, in our PsA cohort, disease duration, maximum SJC, and maximum CRP level had a significant effect on plaque burden. Interestingly, fasting plasma glucose level was also found to influence TPV. Consistent with our results, a recent study evaluating coronary lesions by CCTA in patients with mild to moderate psoriasis who were asymptomatic for CAD showed that fasting blood glucose level was an independent predictor of CAD (48) . Another study using CCTA in severe psoriasis suggested a protective effect of biologic DMARDs on CAD; however, our results do not seem to support this observation (49) .
The strong association between smoking and development of coronary atherosclerosis is well recognized. However, smoking is an undertreated risk factor for CAD, and the role of smoking status in the increased cardiovascular risk is poorly documented in PsA. A recent study using carotid duplex ultrasound identified plaques in 39% of asymptomatic patients with PsA, and patients with carotid plaque trended toward higher rates of smoking and diabetes (50). Gladman et al showed that current smoking status was associated with increased risk of myocardial infarction, but did not increase the risk of CVD in PsA (51). We found a higher presence of coronary plaques, in particular calcified and noncalcified plaques, in PsA patients who had ever smoked compared to those who were nonsmokers, suggesting that smoking may influence coronary plaque burden in PsA. These data support the current knowledge on the effect of smoking on CAD in PsA and suggest that smoking cessation strategies should be a key priority in the care of PsA patients.
The strength of our study is that we performed detailed quantitative and qualitative measurements of coronary plaque burden in a well-characterized and relatively homogenous Irish population with PsA with longterm follow-up of the disease course. Our work has some limitations. While the relationship between PsA and CAD is recognized, more robust studies are needed to evaluate cardiovascular risk factors and their association with plaque burden, particularly in patients with active and more severe forms of the disease. Given that this was a single-center, cross-sectional study with a relatively small sample size, we could not prove causal relationships. Data on waist circumference in the control group was not collected; therefore, we could not tell the exact proportion of patients with metabolic syndrome in the control group. Since most patients had well-controlled disease, we assume that the plaque burden in our cohort may be lower than in those with higher disease activity. Finally, we did not perform carotid ultrasound measurements and therefore could not correlate carotid to coronary plaque burden, which were surprisingly not found to be associated in the study by Shen et al (22) .
In conclusion, we found that patients with wellestablished PsA without symptoms or a diagnosis of CAD had a higher burden of coronary plaques, particularly of mixed type, compared to controls. Our results suggest that accelerated formation of coronary plaques in PsA may associate with underlying disease activity and severity but is independent of features of metabolic syndrome.
